Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00675506 · ClinicalTrials.gov registry record · Phase 2

Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are Obese

A Phase 2 study, sponsored by Massachusetts General Hospital.

Completed
Registry status
Phase 2
Development phase
60
Enrollment target

NCT00675506: Completed Phase 2 study, sponsored by Massachusetts General Hospital.

NCT00675506 is a Phase 2 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 60 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00675506, a Phase 2 study, has completed, sponsored by Massachusetts General Hospital.

COMPLETED
Registry status
Phase 2
Development phase
60 participants
Enrollment target

Study Summary

Obesity, a condition that occurs when a person has too much body fat, affects about 31% of people in the United States. It is associated with increased risk of diabetes, high blood pressure, high cholesterol, and cardiovascular disease. Abdominal obesity, in particular, is also associated with low levels of growth hormone, a hormone that affects rate of growth and the way the body uses energy. Growth hormone releasing hormone (GHRH) is a substance that makes the body naturally increase its own growth hormone levels. Administering GHRH to people who are obese may help return their growth hormone levels to normal and, in turn, may lead to reduced abdominal fat and improved cardiovascular function. This study will evaluate the effectiveness of synthetic GHRH in decreasing the amount of abdominal fat and improving cardiovascular function in people who are obese.

Interventions

  • DRUG Placebo
  • DRUG Growth hormone releasing hormone (GHRH) 1-44

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2008-07
Est. Completion 2012-01
Phase Phase 2

Sponsor

Massachusetts General Hospital

2,032 total trials

What the Registry Record Tells You About NCT00675506

The ClinicalTrials.gov registry entry for NCT00675506 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT00675506 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00675506 about?

NCT00675506 is a clinical study titled "Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are Obese". Obesity, a condition that occurs when a person has too much body fat, affects about 31% of people in the United States. It is associated with increased risk of diabetes, high blood pressure, high cholesterol, and cardiovascular disease. Abdominal obesity, in particular, is also associated with low l...

What is the current status of trial NCT00675506?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2008-07. Estimated completion is 2012-01.

What interventions are being tested in trial NCT00675506?

The interventions under investigation include: Placebo (DRUG), Growth hormone releasing hormone (GHRH) 1-44 (DRUG).

Who is sponsoring clinical trial NCT00675506?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.